Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED)

NCT00812266 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

281

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Extensive Disease
First-Line
Small Cell Lung Cancer

Interventions

DRUG: topotecan + cisplatin
DRUG: Etoposide + carboplatin

Sponsor

Danish Oncological Lung Cancer Group